Organon & financials
$13.74+0.07%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 | FY21 Dec 31 |
|---|---|---|---|---|---|
| Revenue | $6.22B | $6.40B | $6.26B | $6.17B | $6.30B |
| Gross profit | $3.31B | $3.71B | $3.75B | $3.88B | $3.92B |
| Gross margin | 53.3% | 58.0% | 59.8% | 62.8% | 62.2% |
| Operating income | $824.0M | $1.37B | $1.26B | $1.57B | $1.81B |
| Net income | $187.0M | $864.0M | $1.02B | $917.0M | $1.35B |
| Net margin | 3.0% | 13.5% | 16.3% | 14.9% | 21.4% |
| Diluted EPS | $0.72 | $3.33 | $3.99 | $3.59 | $5.31 |
| EBITDA | $1.58B | $1.68B | $1.55B | $1.81B | $2.01B |
| Operating cash flow | $700.0M | $939.0M | $799.0M | $858.0M | $2.46B |
| Free cash flow | $538.0M | $764.0M | $548.0M | $662.0M | $2.27B |
| Diluted shares | 260.8M | 259.2M | 256.3M | 255.2M | 254.2M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|---|
| Cash & equivalents | $574.0M | $675.0M | $693.0M | $706.0M | $737.0M |
| Short-term investments | $0.00 | $0.00 | $0.00 | $0.00 | — |
| Total debt | $8.64B | $8.88B | $8.76B | $8.91B | $9.13B |
| Total assets | $12.87B | $13.10B | $12.06B | $10.96B | $10.68B |
| Total liabilities | $12.12B | $12.63B | $12.13B | $11.85B | $12.19B |
| Shareholders' equity | $752.0M | $472.0M | -$70.0M | -$892.0M | -$1.51B |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology